180 Life Sciences Corp.
ATNF
$0.83
-$0.037-4.27%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -41.81% | -59.27% | -66.01% | -56.02% | -50.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -38.65% | -53.07% | -63.94% | -50.89% | -43.40% |
| Operating Income | 38.65% | 53.07% | 63.94% | 50.89% | 43.40% |
| Income Before Tax | 58.24% | 70.99% | 92.85% | 71.68% | 59.58% |
| Income Tax Expenses | 87.40% | 87.40% | 99.87% | -149.22% | -149.22% |
| Earnings from Continuing Operations | 54.03% | 69.06% | 92.28% | 75.71% | 63.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 54.03% | 69.06% | 92.28% | 75.71% | 63.95% |
| EBIT | 38.65% | 53.07% | 63.94% | 50.89% | 43.40% |
| EBITDA | 38.66% | 53.27% | 64.17% | 51.19% | 43.65% |
| EPS Basic | 70.01% | 78.96% | 98.19% | 93.47% | 89.21% |
| Normalized Basic EPS | 82.85% | 88.75% | 94.13% | 87.71% | 54.30% |
| EPS Diluted | 70.01% | 78.96% | 98.18% | 93.46% | 89.21% |
| Normalized Diluted EPS | 82.85% | 88.75% | 94.13% | 87.71% | 54.30% |
| Average Basic Shares Outstanding | 235.60% | 141.75% | 213.46% | 275.01% | 285.22% |
| Average Diluted Shares Outstanding | 235.60% | 141.75% | 213.46% | 275.01% | 285.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |